Known targets — ChEMBL curated mechanism
ABCC8ACEADORA1ADORA2AADORA2BADORA3ALDH5A1ALOX5ALOX5APATP4AATP4BBRAFCA1CA12CA2CA4CYSLTR1DHFRDPEP1EDNRAEDNRBESR2F10FDPSFGF1GABBR1GABBR2GABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGARTGNRHRGSC1HMGCRIMPDH1IMPDH2KCNJ11LY96NOD2NR3C1NS3NS4ANS5bP2RY1P2RY12P2RY2P2RY4P2RY6PBP2XPDE3APDE3BPDE4APDE4BPDE4CPDE4DPDK1PDK2PDK3PDK4PPARGPPATPTGIRPTGS1PTGS2RAF1RYR1RYR3SCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASERPINC1SLC12A1SLC12A3SYKTHRATHRBTLR3TLR4TLR9TUBA1ATUBA1BTUBA1CTUBA3CTUBA3ETUBA4ATUBBTUBB1TUBB2ATUBB2BTUBB3TUBB4ATUBB4BTUBB6TUBB8TYMSVKORC1XDHblablaIMP-1blaOXA-33blaOXA-58blaT-3blaT-4blaT-5blaT-6dacAdacBdacCfolAfolPfolP1ftsIfusAgaggyrAgyrBmecAmrcAmrcBmrdApbp1apbp1bpbp2pbp2apbp2bpbp3pbp4pbpApbpBpbpCpbpFpolponBrplArplBrplCrplDrplErplFrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmFrpmGrpmHrpmIrpmJrpoArpoBrpoCrpoZrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of None. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | THRB known ✓ | P10828 | 1/20 | 0.88 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.73 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.73 |
| ▸ | TSHR | P16473 | 1/20 | 0.57 |
| ▸ | PTPRA | P18433 | 1/20 | 0.57 |
| ▸ | PTPRB | P23467 | 1/20 | 0.57 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.57 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.57 |
| ▸ | RAPGEF4 | Q8WZA2 | 1/20 | 0.57 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.57 |
| ▸ | PTPN1 | P18031 | 2/20 | 0.55 |
| ▸ | MAPT | P10636 | 3/20 | 0.54 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.54 |
| ▸ | MEN1 | O00255 | 2/20 | 0.54 |
| ▸ | GAA | P10253 | 2/20 | 0.54 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.54 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.54 |
| ▸ | APP | P05067 | 1/20 | 0.54 |
| ▸ | SENP7 | Q9BQF6 | 2/20 | 0.50 |
| ▸ | SUMO2 | P61956 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3196947 | 1.00 | THRB (0.88) | THRBCYP1A2CYP2C9TSHRPTPRA | |
| SCHEMBL29489969 | 1.00 | THRB (0.88) | THRBCYP1A2CYP2C9TSHRPTPRA | |
| E110 SCHEMBL142458 | 0.93 | THRB (1.00) | THRBCYP1A2CYP2C9TSHRPTPRA | |
| E110 SCHEMBL13276157 | 0.93 | THRB (1.00) | THRBCYP1A2CYP2C9TSHRPTPRA | |
| E110 SCHEMBL29350765 | 0.93 | THRB (1.00) | THRBCYP1A2CYP2C9TSHRPTPRA | |
| E110 SCHEMBL323402 | 0.93 | THRB (1.00) | THRBCYP1A2CYP2C9TSHRPTPRA | |
| SCHEMBL30486026 | 0.93 | CYP1A2 (0.83) | THRBCYP1A2CYP2C9TSHRPTPRA | |
| SCHEMBL30940027 | 0.92 | CYP1A2 (0.85) | THRBCYP1A2CYP2C9TSHRPTPRA | |
| SCHEMBL628908 | 0.92 | CYP1A2 (0.85) | THRBCYP1A2CYP2C9TSHRPTPRA | |
| SCHEMBL112146 | 0.92 | CYP1A2 (0.85) | THRBCYP1A2CYP2C9TSHRPTPRA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 67 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220235270-A1 | DEFECT MEDIATED LYOTROPIC NEMATIC GEL | THE UNIVERSITY COURT OF THE UNIVERSITY OF EDINBURGH (GB) | 2022-07-28 | — | — | US | claimed |
| EP-3986979-A1 | DEFECT MEDIATED LYOTROPIC NEMATIC GEL | The University Court Of The University of Edinburgh (GB) | 2022-04-27 | — | — | EP | claimed |
| WO-2020254813-A1 | DEFECT MEDIATED LYOTROPIC NEMATIC GEL | THE UNIVERSITY COURT OF THE UNIVERSITY OF EDINBURGH (GB) | 2020-12-24 | — | — | WO | claimed |
| WO-2019216829-A1 | APPLICATION OF A FOOD AZO DYE, BRILLIANT BLACK BN, ON INHIBITION OF INFECTIVITY OF HUMAN ENTEROVIRUSES CAUSING HAND FOOT AND MOUTH DISEASES | TEMASEK LIFE SCIENCES LABORATORY LIMITED (SG) | 2019-11-14 | — | — | WO | claimed |
| US-12491157-B1 | Atomoxetine hydrochloride oral suspension and use thereof | OWP Pharmaceuticals, Inc. | 2025-12-09 | — | — | US | disclosed |
| US-12478584-B1 | Atomoxetine hydrochloride oral suspension and use thereof | OWP PHARMACEUTICALS INC (US) | 2025-11-25 | — | — | US | disclosed |
| US-12460135-B2 | System comprising a nematic liquid crystal and an interface | THE UNIVERSITY COURT OF THE UNIVERSITY OF EDINBURGH (GB) | 2025-11-04 | — | — | US | disclosed |
| EP-4054523-B1 | ORALLY ADMINISTRABLE FILMS COMPRISING POORLY WATER SOLUBLE ACTIVE INGREDIENTS AND PREPARATION THEREOF | BIOTA LTD (IL) | 2025-08-06 | — | — | EP | disclosed |
| EP-3986979-B1 | DEFECT MEDIATED LYOTROPIC NEMATIC GEL | UNIV COURT UNIV OF EDINBURGH (GB) | 2025-07-30 | — | — | EP | disclosed |
| US-12332254-B2 | Systems, compositions, and methods for evaluating biomechanical properties of cells | CORNELL UNIVERSITY (US) | 2025-06-17 | — | — | US | disclosed |
| US-12012541-B2 | Defect mediated lyotropic nematic gel | THE UNIVERSITY COURT OF THE UNIVERSITY OF EDINBURGH (GB) | 2024-06-18 | — | — | US | disclosed |
| US-20240158696-A1 | A SYSTEM COMPRISING A NEMATIC LIQUID CRYSTAL AND AN INTERFACE | THE UNIVERSITY COURT OF THE UNIVERSITY OF EDINBURGH (GB) | 2024-05-16 | — | — | US | disclosed |
| US-20060121070-A1 | Dyestuff for keratin fibers | HFC PRESTIGE INTERNATIONAL HOLDING SWITZERLAND S.A.R.L (CH) | 2006-06-08 | — | — | US | disclosed |
| US-7018426-B2 | Oxidation dye | WELLA AG (DE) | 2006-03-28 | — | — | US | disclosed |
| US-20060047172-A1 | M-diaminobenzenes, their acid adducts and the use thereof in colorants | Wella GmbH (DE) | 2006-03-02 | — | — | US | disclosed |
| US-20040098815-A1 | Coluoring agent for keratin fibres | HFC PRESTIGE INTERNATIONAL HOLDING SWITZERLAND S.A.R.L (CH) | 2004-05-27 | — | — | US | disclosed |
| US-20030159222-A1 | Oxidation dye | HFC PRESTIGE INTERNATIONAL HOLDING SWITZERLAND S.A.R.L (CH) | 2003-08-28 | — | — | US | disclosed |
| US-20020189031-A1 | Use of salts for improving the absorption qualities of anionic direct dyes | WELLA AKTIENGESELLSCHAFT (DE) | 2002-12-19 | — | — | US | disclosed |
| US-6379400-B1 | DYEING FIBERS, SOLVENT OF WATER OR ALCOHOL AND NITROANILINE DYE | WELLA AKTIENGESELLSCHAFT (DE) | 2002-04-30 | — | — | US | disclosed |
| EP-0177920-A2 | Pharmaceutical composition for external use containing active type vitam D3 | TEIJIN LIMITED (JP) | 1986-04-16 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12491157-B1 | Atomoxetine hydrochloride oral suspension and use thereof | SLC6A4, SLC6A3, MBOAT4 | THRB 1816/4885CYP1A2 1334/4885CYP2C9 891/4885 |
| US-20030159222-A1 | Oxidation dye | KRT18, NOX4, VIM | THRB 3444/4885CYP1A2 384/4885CYP2C9 1339/4885 |
| US-20060047172-A1 | M-diaminobenzenes, their acid adducts and the use thereof in colorants | DDT, NQO1, MDH2 | THRB 2956/4885CYP1A2 359/4885CYP2C9 436/4885 |
| US-12478584-B1 | Atomoxetine hydrochloride oral suspension and use thereof | SLC6A4, SLC6A3, MBOAT4 | THRB 1816/4885CYP1A2 1334/4885CYP2C9 891/4885 |
| US-20040098815-A1 | Coluoring agent for keratin fibres | KRT18, DSG1, KIF5B | THRB 4724/4885CYP1A2 1510/4885CYP2C9 3442/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.